Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Nick who wrote (714)	4/16/1998 4:31:00 PM
From: Nick	Respond to of 1580

Merck reaffirms faith in 14-18 pct '98 EPS Similarly, Merck said first quarter Pepcid sales increased 14 percent to $320 million on a 23 percent jump in the U.S. But overseas revenues from the drug dropped 38 percent. Merck said worldwide sales of Mevacor, an older member of the ''statin'' family of anti-cholesterol drugs, fell 36 percent to $175 million. Sales of Cozaar and companion drug Hyzaar jumped 68 percent to $215 million; Crixivan sales jumped 22 percent to $150 million; hypertension drug Prinivil rose 20 percent to $150 million; Fosamax leaped 76 percent to $180 million; and Vasotec fell two percent to $615 million. Analysts said Merck's revenue picture could improve later in the year with expected marketing approvals and launches of two other drugs -- Maxalt for migraine headaches and anti-platelet drug Aggrastat for preventing heart attac